Preserving Patient Access to Home Infusion Act
Summary
The Preserving Patient Access to Home Infusion Act (S.1058) expands Medicare Part B coverage for home infusion therapy, explicitly including pharmacy services and non-pump drugs, and removes the physical presence requirement for per-day payment. This structurally raises addressable revenue for CVS Health's Coram and UnitedHealth Group's Optum infusion businesses. Both stocks show strong momentum — CVS up 15.75% and UNH up 34.54% over 30 days — though the bill is at early legislative stage (referred to committee).
See which stocks are affected
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
Key Takeaways
- 1.S.1058 expands Medicare home infusion coverage to include pharmacy services and non-pump drugs, directly benefiting CVS/Coram and UNH/Optum infusion businesses.
- 2.The bill removes the physical presence requirement for per-day payment and establishes a 5-hour infusion day payment floor (2026-2030), structurally raising per-patient reimbursement.
- 3.Early-stage bipartisan bill with companion House legislation; no hearings scheduled yet, but the transitional rule start date (Jan 2026) suggests sponsors target passage within 12-18 months.
Market Implications
CVS Health ($83.13) and UnitedHealth Group ($364.05) are the two publicly traded companies most directly positioned to benefit from expanded Medicare home infusion coverage. CVS's Coram is the market leader in home infusion, and Optum Infusion Services is the second-largest national provider. The 30-day momentum in both stocks (CVS +15.75%, UNH +34.54%) partly reflects broader healthcare sector rotation, but this bill adds a specific structural revenue tailwind. At current prices, both are near 52-week highs. The legislative risk is that the bill stalls in committee or is amended substantively, but bipartisan sponsorship and the companion House bill reduce that probability. Investors should monitor the Senate Finance Committee schedule for markups.
Full Analysis
Intelligence Surface
Cross-referenced against federal contracts, SEC insider filings & congressional trade disclosures
Some confirming evidence found across public data sources
What the bill does
Medicare coverage expansion: the bill explicitly includes pharmacy services and non-pump infusion drugs under home infusion therapy, and removes the requirement for a qualified supplier to be physically present for payment to be made on a per-day basis.
Who must act
Centers for Medicare & Medicaid Services (CMS) — must revise Medicare Part B payment rules for home infusion therapy to cover pharmacy services and non-pump drug administration days regardless of physical presence.
What happens
CMS will reimburse CVS Health's Coram home infusion business for an additional revenue stream (pharmacy services) and for drug administration days that previously did not qualify for payment because a supplier was not physically present in the home. The transitional rule (2026-2030) also guarantees payment based on 5 hours of infusion per day, increasing per-day reimbursement rates for therapies that previously may have been reimbursed for fewer hours.
Stock impact
CVS Health's Coram division is one of the largest home infusion providers in the US. Expanding Medicare Part B coverage directly increases addressable revenue for Coram by adding pharmacy service fees and eliminating the physical presence barrier that previously left many administration days unbillable. Coram operates within CVS's Health Services segment (~40% of CVS revenue), and this bill structurally raises the revenue ceiling for that portion of the business.
What the bill does
Same as above — Medicare coverage expansion for pharmacy services and non-pump infusion drugs, with revised payment rules removing the physical presence requirement and establishing a 5-hour infusion day payment floor (2026-2030).
Who must act
Centers for Medicare & Medicaid Services (CMS) — must revise Medicare Part B payment rules for home infusion therapy.
What happens
CMS will reimburse Optum's home infusion business for pharmacy services and for previously unbillable administration days (when a supplier was not physically present). The 5-hour infusion day payment floor increases per-day reimbursement for certain therapies.
Stock impact
UnitedHealth Group's Optum division operates a large home infusion business through Optum Infusion Services. Expanded Medicare coverage directly increases Optum's addressable revenue from pharmacy services and eliminates the physical presence reimbursement barrier. Optum contributes ~45% of UNH's total revenue, and home infusion is a growing sub-segment within Optum's Care Delivery arm. The bill structurally increases the per-patient revenue opportunity from Medicare home infusion patients.
Market Impact Score
Connected Signals
Matched on shared policy language across AI analyses, with ticker & timing weight
Consolidated Appropriations Act, 2026
Protecting Health Care and Lowering Costs Act of 2025
To amend title XVIII of the Social Security Act to ensure stability for provider payments under the Medicare program.
TRIWEST HEALTHCARE ALLIANCE CORP: $820M Department of Veterans Affairs Contract
Association Health Plans Act
Protecting Health Care and Lowering Costs Act
Veterans’ ACCESS Act of 2025
I CAN Act
Related Presidential Actions
Executive orders & memoranda affecting the same sectors or companies
Promoting Efficiency, Accountability, and Performance in Federal Contracting
This executive order mandates that federal agencies default to using fixed-price contracts for procurement, shifting away from cost-reimbursement models. It requires written justification and senior-level approval for any non-fixed-price contract over certain dollar thresholds (e.g., $10M for most agencies, $100M for the Department of War), and directs agencies to review and renegotiate their 10 largest non-fixed-price contracts within 90 days. The order also tasks OMB with implementation guidance and the Federal Acquisition Regulatory Council with proposing regulatory amendments within 120 days.
Accelerating Medical Treatments for Serious Mental Illness
This executive order directs the FDA to prioritize review and facilitate 'Right to Try' access for psychedelic drugs, including ibogaine compounds, that have received Breakthrough Therapy designation for serious mental illnesses. It also allocates $50 million from HHS to support state programs advancing these treatments and mandates collaboration between HHS, FDA, VA, and the private sector to increase clinical trial participation and data sharing for these drugs. The Attorney General is further directed to expedite rescheduling reviews for approved Schedule I psychedelic substances.